Cmax evidence

Peptide

ATLPC0008117

Measured material

Specific molecular form

Endpoint

Cmax

ADMET domain

Exposure / Absorption

Value

Observation

A dose-dependent increase in C max and AUC 0-INF was also observed between carfilzomib 20 mg/m 2 and 56 mg/m 2 as a 2- to 10-minute infusion in patients with relapsed or refractory multiple myeloma.

Evidence role

Reported: reviewed reported observation that should not be pooled as a comparable value yet

Assay / model

human

Condition

Carfilzomib · ea66eb30-e665-4693-99a1-a9d3b4bbe2d6 · 12.3 Pharmacokinetics · cmax auc dose dependent increase text · A dose-dependent increase in C max and AUC 0-INF was also obse...

Scientific source

DailyMed

Open source

Cmax evidence

Developability

Resources

Measurement